133 related articles for article (PubMed ID: 36730351)
1. The Correlation of Diabetes Mellitus and Urinary Retention From Intravesical OnabotulinumtoxinA Injection for Overactive Bladder.
Takashima Y; Handler S; Laus K; Eckhardt S; Whitaker T; Tenggardjaja C; Yazdany T
Urogynecology (Phila); 2023 May; 29(5):511-519. PubMed ID: 36730351
[TBL] [Abstract][Full Text] [Related]
2. What is the true catheterization rate after intravesical onabotulinumtoxinA injection?
Patel DN; Jamnagerwalla J; Houman J; Anger JT; Eilber KS
Int Urogynecol J; 2018 Jul; 29(7):1005-1009. PubMed ID: 28808734
[TBL] [Abstract][Full Text] [Related]
3. Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder.
Liberman D; Milhouse O; Johnson-Mitchell M; Siegel SW
Female Pelvic Med Reconstr Surg; 2018; 24(6):404-407. PubMed ID: 28953573
[TBL] [Abstract][Full Text] [Related]
4. Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings.
Kennelly M; Green L; Alvandi N; Wehbe S; Smith JJ; MacDiarmid S; Mangel J; Schwartz M; Aboushwareb T; Murray B
Curr Med Res Opin; 2018 Oct; 34(10):1771-1776. PubMed ID: 29458265
[TBL] [Abstract][Full Text] [Related]
5. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.
Osborn DJ; Kaufman MR; Mock S; Guan MJ; Dmochowski RR; Reynolds WS
Neurourol Urodyn; 2015 Sep; 34(7):675-8. PubMed ID: 24975819
[TBL] [Abstract][Full Text] [Related]
6. Risk of Retention After OnabotulinumtoxinA Injection for Overactive Bladder in a Diverse Urban Population With High BMI and Comorbidity Rates.
Aalami Harandi A; Nauheim J; Abraham NE
Urogynecology (Phila); 2023 Jan; 29(1):41-47. PubMed ID: 36548104
[TBL] [Abstract][Full Text] [Related]
7. Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery.
Liao CH; Wang CC; Jiang YH
Toxins (Basel); 2016 Mar; 8(4):91. PubMed ID: 27023603
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.
Kuo HC; Liu HT; Chuang YC; Birder LA; Chancellor MB
Eur Urol; 2014 Jun; 65(6):1117-24. PubMed ID: 24555904
[TBL] [Abstract][Full Text] [Related]
9. Real-Life Treatment Outcome of Botulinum Toxin A Injection on Overactive Bladder and Voiding Dysfunction in Patients with Central Nervous System Lesions.
Jiang YH; Jhang JF; Chen SF; Kuo HC
Toxins (Basel); 2024 Mar; 16(3):. PubMed ID: 38535789
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?
Kuo YC; Kuo HC
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999201
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
Jiang YH; Ong HL; Kuo HC
Neurourol Urodyn; 2017 Jan; 36(1):142-147. PubMed ID: 26417884
[TBL] [Abstract][Full Text] [Related]
12. Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: Multi-institutional collaboration from the SUFU research network.
Reynolds WS; Suskind AM; Anger JT; Brucker BM; Cameron AP; Chung DE; Daignault-Newton S; Lane GI; Lucioni A; Mourtzinos AP; Padmanabhan P; Reyblat PX; Smith AL; Tenggardjaja CF; Lee UJ;
Neurourol Urodyn; 2022 Feb; 41(2):662-671. PubMed ID: 35019167
[TBL] [Abstract][Full Text] [Related]
13. Are we underestimating urinary retention following intravesical onabotulinumtoxinA in women with overactive bladder and a history of prior pelvic surgery?
Holmes A; Kelsey E; Wombwell A; Molesworth C; McLeod K
Neurourol Urodyn; 2023 Jan; 42(1):106-112. PubMed ID: 36183370
[TBL] [Abstract][Full Text] [Related]
14. Urinary retention in female OAB after intravesical Botox injection: who is really at risk?
Miotla P; Cartwright R; Skorupska K; Bogusiewicz M; Markut-Miotla E; Futyma K; Rechberger T
Int Urogynecol J; 2017 Jun; 28(6):845-850. PubMed ID: 27889830
[TBL] [Abstract][Full Text] [Related]
15. Routine Office Assessment After OnabotulinumtoxinA Injection for Overactive Bladder Is Unnecessary to Detect Clinically Significant Voiding Dysfunction.
Aldrich ER; Pauls RN
Female Pelvic Med Reconstr Surg; 2021 Apr; 27(4):225-229. PubMed ID: 33770805
[TBL] [Abstract][Full Text] [Related]
16. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis.
Cui Y; Zhou X; Zong H; Yan H; Zhang Y
Neurourol Urodyn; 2015 Jun; 34(5):413-9. PubMed ID: 24676791
[TBL] [Abstract][Full Text] [Related]
18. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity.
Wang CC; Liao CH; Kuo HC
Neurourol Urodyn; 2014 Nov; 33(8):1235-9. PubMed ID: 24115083
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder.
Jiang YH; Liao CH; Tang DL; Kuo HC
PLoS One; 2014; 9(8):e105989. PubMed ID: 25148378
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder.
Eckhardt SE; Takashima Y; Handler SJ; Tenggardjaja C; Yazdany T
Int Urogynecol J; 2022 Mar; 33(3):703-709. PubMed ID: 33594517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
